Advancing Next-Generation Therapeutics with Engineered Biology to Disrupt the Current GLP-1 Paradigm for Enhanced Treatment Diversity & Commercial Viability
- Utilizing engineered protein translation and the incorporation of Non-Canonical Amino Acids (ncAAs) for creating new-to-nature biotherapeutics, enabling drug candidates with improved stability, efficacy, and novel mechanisms of action beyond traditional incretin agonism
- Exploring how sustainable, aqueous biomanufacturing is strategically essential to overcome the high cost and inefficiency of existing chemical synthesis methods, ensuring that next-generation peptide therapeutics can meet massive global demand
- Prioritizing platform technologies in commercialization strategy that enable rapid, cost-effective scale up and yielding differentiated products, moving the field past dose-optimization of existing drugs toward wholly novel, patient-focused treatments